Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia-Reference-Cited by-同舟云学术

Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia

Published:2014-06-11 Issue:10 Volume:61 Page:1761-1766
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Zhang Li¹,Cao Zeng¹,Ruan Min¹,Zeng Qiang²,Zhao Liang²,Li Qinghua¹,Zou Yao¹,Wang Jianxiang³,Zhu Xiaofan¹

Affiliation:

1. Department of Pediatrics; State Key Laboratory of Experimental Hematology; Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Tianjin P.R. China

2. Tianjin Centers for Disease Control and Prevention; Tianjin P.R. China

3. State Key Laboratory of Experimental Hematology; Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Tianjin P.R. China

Funder

Tianjin Science and Technology Support Plan

Ministry of Science and Technology Major Projects

Youth Scientific Research Funds of Peking Union Medical College

Natural Science Fund Foundation Project

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.25109/fullpdf

Reference26 articles.

1. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12;Harrison;J Clin Oncol,2010

2. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98;von Neuhoff;J Clin Oncol,2010

3. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 882;Raimondi;Blood,1999

4. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered;Byrd;J Clin Oncol,1999

5. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study;Marcucci;J Clin Oncol,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia;BMC Cancer;2024-01-09

2. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024

3. Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study;Blood Cancer Journal;2023-11-13

4. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis;Leukemia;2022-10-19

5. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia;International Journal of Laboratory Hematology;2022-08-02